A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary

Authors: Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Massey, A., Prior, Y. and Hill, M.E.

Journal: European Journal of Cancer

Volume: 39

Issue: 8

Pages: 1121-1128

ISSN: 0959-8049

DOI: 10.1016/S0959-8049(03)00150-3

Abstract:

No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C (MMC) in patients with CUP in a multicentre, prospectively randomised study. 88 patients were randomised to PVI 5-FU (300 mg/m2/day for a maximum of 24 weeks) ±MMC (7 mg/m2 6 weekly for four courses). The overall response rate was 11.6% for PVI 5-FU alone compared with 20.0% for PVI 5-FU plus MMC (P=0.29). Median failure-free survival (FFS) was 4.1 months for PVI 5-FU and 3.6 months for PVI 5-FU plus MMC (P=0.78) with an equivalent overall survival (OS) (6.6 versus 4.7 months, P=0.60). Symptomatic benefit was observed in most patients in each arm. PVI 5-FU is a well tolerated outpatient treatment regimen for patients with CUP, although the addition of MMC provides little extra benefit. PVI 5-FU may be a potential reference regimen in randomised trials with newer chemotherapy agents in patients with CUP. © 2003 Elsevier Science Ltd. All rights reserved.

Source: Scopus

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.

Authors: Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Massey, A., Prior, Y. and Hill, M.E.

Journal: Eur J Cancer

Volume: 39

Issue: 8

Pages: 1121-1128

ISSN: 0959-8049

DOI: 10.1016/s0959-8049(03)00150-3

Abstract:

No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C (MMC) in patients with CUP in a multicentre, prospectively randomised study. 88 patients were randomised to PVI 5-FU (300 mg/m(2)/day for a maximum of 24 weeks) +/-MMC (7 mg/m(2) 6 weekly for four courses). The overall response rate was 11.6% for PVI 5-FU alone compared with 20.0% for PVI 5-FU plus MMC (P=0.29). Median failure-free survival (FFS) was 4.1 months for PVI 5-FU and 3.6 months for PVI 5-FU plus MMC (P=0.78) with an equivalent overall survival (OS) (6.6 versus 4.7 months, P=0.60). Symptomatic benefit was observed in most patients in each arm. PVI 5-FU is a well tolerated outpatient treatment regimen for patients with CUP, although the addition of MMC provides little extra benefit. PVI 5-FU may be a potential reference regimen in randomised trials with newer chemotherapy agents in patients with CUP.

Source: PubMed

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary

Authors: Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Massey, A., Prior, Y. and Hill, M.E.

Journal: EUROPEAN JOURNAL OF CANCER

Volume: 39

Issue: 8

Pages: 1121-1128

ISSN: 0959-8049

DOI: 10.1016/S0959-8049(03)00150-3

Source: Web of Science (Lite)

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary

Authors: Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T.J., Seymour, M.T.J., Hickish, T.F., Massey, A., Prior, Y. and Hilla, M.E.

Journal: European Journal of Cancer

Volume: 39

Pages: 1121-1128

ISSN: 0959-8049

DOI: 10.1016/S0959-8049(03)00150-3

Abstract:

No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C (MMC) in patients with CUP in a multicentre, prospectively randomised study. 88 patients were randomised to PVI 5-FU (300 mg/m2/day for a maximum of 24 weeks) ±MMC (7 mg/m2 6 weekly for four courses). The overall response rate was 11.6% for PVI 5-FU alone compared with 20.0% for PVI 5-FU plus MMC (P=0.29). Median failure-free survival (FFS) was 4.1 months for PVI 5-FU and 3.6 months for PVI 5-FU plus MMC (P=0.78) with an equivalent overall survival (OS) (6.6 versus 4.7 months, P=0.60). Symptomatic benefit was observed in most patients in each arm. PVI 5-FU is a well tolerated outpatient treatment regimen for patients with CUP, although the addition of MMC provides little extra benefit. PVI 5-FU may be a potential reference regimen in randomised trials with newer chemotherapy agents in patients with CUP.

http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T68-48CNJ0J-3&_user=1682380&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_version=1&_urlVersion=0&_userid=1682380&md5=da8ac834e4a639b330059d3e22609f47

Source: Manual

Preferred by: Tamas Hickish

A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.

Authors: Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T., Seymour, M., Hickish, T., Massey, A., Prior, Y. and Hill, M.E.

Journal: European journal of cancer (Oxford, England : 1990)

Volume: 39

Issue: 8

Pages: 1121-1128

eISSN: 1879-0852

ISSN: 0959-8049

DOI: 10.1016/s0959-8049(03)00150-3

Abstract:

No standard regimen has been identified for patients with a carcinoma of unknown primary (CUP). This study compared protracted venous infusion 5-fluorouracil (PVI 5-FU) with or without mitomycin C (MMC) in patients with CUP in a multicentre, prospectively randomised study. 88 patients were randomised to PVI 5-FU (300 mg/m(2)/day for a maximum of 24 weeks) +/-MMC (7 mg/m(2) 6 weekly for four courses). The overall response rate was 11.6% for PVI 5-FU alone compared with 20.0% for PVI 5-FU plus MMC (P=0.29). Median failure-free survival (FFS) was 4.1 months for PVI 5-FU and 3.6 months for PVI 5-FU plus MMC (P=0.78) with an equivalent overall survival (OS) (6.6 versus 4.7 months, P=0.60). Symptomatic benefit was observed in most patients in each arm. PVI 5-FU is a well tolerated outpatient treatment regimen for patients with CUP, although the addition of MMC provides little extra benefit. PVI 5-FU may be a potential reference regimen in randomised trials with newer chemotherapy agents in patients with CUP.

Source: Europe PubMed Central